FDA Clears Medtronic MiniMed 780G for Type 2 Diabetes, Abbott Sensor Integration

Medtronic has received two key FDA approvals for its MiniMed 780G system, significantly expanding its use and integration capabilities. The FDA cleared the SmartGuard algorithm as an interoperable automated glycemic controller, enabling integration with Abbott’s Instinct sensor for type 1 diabetes, and approved the system for adults with insulin-requiring type 2 diabetes. These milestones complete the regulatory pathway for the Instinct sensor integration and mark the MiniMed 780G as the first automated insulin delivery system with Meal Detection technology available for type 2 diabetes patients. Medtronic's expansion into the type 2 diabetes market broadens its customer base and strengthens its position in diabetes management technology. The company is also preparing to separate its Diabetes business into a standalone, publicly traded entity, though regulatory compliance and market integration processes are ongoing. Overall, these developments advance a smart dosing ecosystem offering greater flexibility and a more seamless experience for people living with diabetes.